Cancer Discovery,
Journal Year:
2021,
Volume and Issue:
11(4), P. 874 - 899
Published: April 1, 2021
Resistance
to
anticancer
therapies
includes
primary
resistance,
usually
related
lack
of
target
dependency
or
presence
additional
targets,
and
secondary
mostly
driven
by
adaptation
the
cancer
cell
selection
pressure
treatment.
targeted
therapy
is
frequently
acquired,
on-target,
bypass
alterations,
cellular
plasticity.
immunotherapy
often
primary,
orchestrated
sophisticated
tumor-host-microenvironment
interactions,
but
could
also
occur
after
initial
efficacy,
when
only
partial
responses
are
obtained.
Here,
we
provide
an
overview
resistance
tumor
immune-targeted
discuss
challenges
overcoming
current
future
directions
development.
SIGNIFICANCE:
A
better
earlier
identification
cancer-resistance
mechanisms
avoid
use
ineffective
drugs
in
patients
not
responding
rationale
for
administration
personalized
drug
associations.
clear
description
molecular
interplayers
a
prerequisite
development
novel
dedicated
drugs.
Finally,
implementation
such
immunologic
explorations
prospective
clinical
trials
de-risk
demonstration
more
effective
strategies
randomized
registration
trials,
bring
us
closer
promise
cure.
Signal Transduction and Targeted Therapy,
Journal Year:
2022,
Volume and Issue:
7(1)
Published: Jan. 3, 2022
Abstract
The
Wnt/β-catenin
pathway
comprises
a
family
of
proteins
that
play
critical
roles
in
embryonic
development
and
adult
tissue
homeostasis.
deregulation
signalling
often
leads
to
various
serious
diseases,
including
cancer
non-cancer
diseases.
Although
many
articles
have
reviewed
from
aspects,
systematic
review
encompassing
the
origin,
composition,
function,
clinical
trials
tumour
diseases
is
lacking.
In
this
article,
we
comprehensively
above
five
aspects
combination
with
latest
research.
Finally,
propose
challenges
opportunities
for
small-molecular
compounds
targeting
Wnt
disease
treatment.
Cell Death and Disease,
Journal Year:
2020,
Volume and Issue:
11(11)
Published: Nov. 26, 2020
Abstract
Chemotherapy,
radiation
therapy,
as
well
targeted
anticancer
agents
can
induce
clinically
relevant
tumor-targeting
immune
responses,
which
critically
rely
on
the
antigenicity
of
malignant
cells
and
their
capacity
to
generate
adjuvant
signals.
In
particular,
immunogenic
cell
death
(ICD)
is
accompanied
by
exposure
release
numerous
damage-associated
molecular
patterns
(DAMPs),
altogether
confer
a
robust
adjuvanticity
dying
cancer
cells,
they
favor
recruitment
activation
antigen-presenting
cells.
ICD-associated
DAMPs
include
surface-exposed
calreticulin
(CALR)
secreted
ATP,
annexin
A1
(ANXA1),
type
I
interferon,
high-mobility
group
box
1
(HMGB1).
Additional
hallmarks
ICD
encompass
phosphorylation
eukaryotic
translation
initiation
factor
2
subunit-α
(EIF2S1,
better
known
eIF2α),
autophagy,
global
arrest
in
transcription
translation.
Here,
we
outline
methodological
approaches
for
measuring
markers
vitro
ex
vivo
discovery
next-generation
antineoplastic
agents,
development
personalized
regimens,
identification
optimal
therapeutic
combinations
clinical
management
cancer.
Frontiers in Immunology,
Journal Year:
2020,
Volume and Issue:
11
Published: May 15, 2020
The
success
of
cancer
immunotherapy
relies
on
the
knowledge
tumor
microenvironment
and
immune
evasion
mechanisms
in
which
tumor,
stroma
infiltrating
cells
function
a
complex
network.
potential
barriers
that
profoundly
challenge
overall
clinical
outcome
promising
therapies
need
to
be
fully
identified
counteracted.
Although
has
increasingly
been
applied,
we
are
far
from
understanding
how
utilize
different
strategies
best
way
combine
therapeutic
options
optimize
benefit.
This
review
intends
give
contemporary
detailed
overview
roles
cells,
exosomes
molecules
acting
they
relate
activation
escape.
Further,
current
novel
immunotherapeutic
will
discussed.
